Factor H is a member of the regulators of complement activation family and is a complement control protein. It is a large (155 kilodaltons), soluble glycoprotein that circulates in human plasma (at typical concentrations of 200–300 micrograms per milliliter). Its principal function is to regulate the Alternative Pathway of the complement system, ensuring that the complement system is directed towards pathogens or other dangerous material and does not damage host tissue. Factor H regulates complement activation on self cells and surfaces by possessing both cofactor activity for the Factor I mediated C3b cleavage, and decay accelerating activity against the alternative pathway C3-convertase, C3bBb. Factor H exerts its protective action on self cells and self surfaces but not on the surfaces of bacteria or viruses, because it binds to glycosaminoglycans (GAGs) that are generally present on host cells but not, normally, on pathogen surfaces.
The molecule is made up of 20 complement control protein (CCP) modules (also referred to as Short Consensus Repeats or sushi domains) connected to one another by short linkers (of between three and eight amino acid residues) and arranged in an extended head to tail fashion. Each of the CCP modules consists of around 60 amino acids with four cysteine residues disulfide bonded in a 1-3 2-4 arrangement, and a hydrophobic core built around an almost invariant tryptophan residue. The CCP modules are numbered from 1-20 (from the N-terminus of the protein); CCPs 1-4 and CCPs 19-20 engage with C3b while CCPs 7 and CCPs 19-20 bind to GAGs and sialic acid. To date atomic structures have been determined for CCPs 1-3, CCP 5, CCP 7 (both 402H & 402Y), CCPs 10-11 and CCPs 11-12, CCPs 12-13, CCP 15, CCP 16, CCPs 15-16, CCPs 18-20, and CCPs 19-20. The atomic structure for CCPs 6-8 (402H) bound to the GAG mimic sucrose octasulfate, CCPs 1-4 in complex with C3b and CCPs 19-20 in complex with C3d (that corresponds to the thioster domain of C3b) have also been determined. Although an atomic resolution structure for intact factor H has not yet been determined, low resolution techniques indicate that it may be bent back in solution. Information available to date indicates that CCP modules 1-4 is responsible for the cofactor and decay acceleration activities of factor H, whereas self/non-self discrimination occurs predominantly through GAG binding to CCP modules 7 and/or 19-20.
Due to the central role that factor H plays in the regulation of complement, there are a number of clinical implications arrising from aberrant factor H activity. Overactive factor H may result in reduced complement activity on pathogenic cells - increasing susceptibility to microbial infections. Underactive factor H may result in increased complement activity on healthy host cells - resulting in autoimmune diseases. It is not surprising therefore that mutations or single nucleotide polymorphisms (SNPs) in factor H often result in pathologies. Moreover the complement inhibitory activities of factor H, and other complement regulators, are often used by pathogens to increase virulence.
Recently it was discovered that about 35% of individuals carry an at-risk SNP in one or both copies of their factor H gene. Homozygous individuals have an approximately sevenfold increased chance of developing age-related macular degeneration, while heterozygotes have a two-to-threefold increased likelihood of developing the disease. This SNP, located in CCP module 7 of factor H, has been shown to affect the interaction between factor H and heparin indicating a causal relationship between the SNP and disease. Deletion of two adjacent genes with a high degree of homology to complement factor H, named complement factor H-related 3 and complement factor H-related 1, protects against age-related macular degeneration because of reduced competition for binding of CFH to vascular surface binding sites.
Haemolytic uraemic syndrome (HUS) is a disease associated with microangiopathic haemolytic anemia, thrombocytopenia and acute renal failure. A rare subset of this disease (referred to as atypical haemolytic uraemic syndrome, aHUS), has been strongly linked to mutations in genes of the complement system (including factor H, factor I and membrane cofactor protein), with the factor H mutations being the most numerous. These factor H mutations tend to congregate towards the C-terminus of factor H—a region responsible for discriminating self from non-self—and have been shown to disrupt heparin (a model compound for glycosaminoglycans) and C3d (equivalent to the thioester domain of C3b) binding.
^Hakobyan, S.; Harris, CL.; Tortajada, A.; Goicochea de Jorge, E.; García-Layana, A.; Fernández-Robredo, P.; Rodríguez de Córdoba, S.; Morgan, BP. (May 2008). "Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration.". Invest Ophthalmol Vis Sci49 (5): 1983–90. doi:10.1167/iovs.07-1523. PMID18436830.
^Pangburn MK (August 2000). "Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement". Immunopharmacology49 (1–2): 149–57. doi:10.1016/S0162-3109(00)80300-8. PMID10904114.
^Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P (June 2004). "The human complement factor H: functional roles, genetic variations and disease associations". Mol. Immunol.41 (4): 355–67. doi:10.1016/j.molimm.2004.02.005. PMID15163532.
^Schmidt, CQ.; Herbert, AP.; Kavanagh, D.; Gandy, C.; Fenton, CJ.; Blaum, BS.; Lyon, M.; Uhrín, D. et al. (Aug 2008). "A new map of glycosaminoglycan and C3b binding sites on factor H.". J Immunol181 (4): 2610–9. PMID18684951.|displayauthors= suggested (help)
^Barlow PN, Norman DG, Steinkasserer A, Horne TJ, Pearce J, Driscoll PC, Sim RB, Campbell ID. (1992). "Solution structure of the fifth repeat of factor H: a second example of the complement control protein module". Biochemistry.31 (14): 3626–34. doi:10.1021/bi00129a011. PMID1533152.
^ abHerbert AP, Deakin JA, Schmidt CQ, Blaum BS, Egan C, Ferreira VP, Pangburn MK, Lyon M, Uhrín D, Barlow PN (June 2007). "Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism". J. Biol. Chem.282 (26): 18960–8. doi:10.1074/jbc.M609636200. PMID17360715.
^Makou, E.; Mertens, HD.; Maciejewski, M.; Soares, DC.; Matis, I.; Schmidt, CQ.; Herbert, AP.; Svergun, DI. et al. (Dec 2012). "Solution Structure of CCP Modules 10-12 Illuminates Functional Architecture of the Complement Regulator, Factor H.". J Mol Biol424 (5): 295–312. doi:10.1016/j.jmb.2012.09.013. PMID23017427.|displayauthors= suggested (help)
^Norman DG, Barlow PN, Baron M, Day AJ, Sim RB, Campbell ID. (1991). "Three-dimensional structure of a complement control protein module in solution". J Mol Biol.219 (4): 717–25. doi:10.1016/0022-2836(91)90666-T. PMID1829116.
^Barlow PN, Steinkasserer A, Norman DG, Kieffer B, Wiles AP, Sim RB, Campbell ID. (1993). "Solution structure of a pair of complement modules by nuclear magnetic resonance". J Mol Biol.232 (1): 268–84. doi:10.1006/jmbi.1993.1381. PMID8331663.
^Morgan, HP.; Mertens, HD.; Guariento, M.; Schmidt, CQ.; Soares, DC.; Svergun, DI.; Herbert, AP.; Barlow, PN. et al. (2012). "Structural analysis of the C-terminal region (modules 18-20) of complement regulator factor H (FH).". PLoS ONE7 (2): e32187. doi:10.1371/journal.pone.0032187. PMID22389686.|displayauthors= suggested (help)
^Herbert AP, Uhrín D, Lyon M, Pangburn MK, Barlow PN. (march 2006). "Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure". J Biol Chem.281 (24): 16512–20. doi:10.1074/jbc.M513611200. PMID16533809.Check date values in: |date= (help)
^Morgan, HP.; Schmidt, CQ.; Guariento, M.; Blaum, BS.; Gillespie, D.; Herbert, AP.; Kavanagh, D.; Mertens, HD. et al. (Apr 2011). "Structural basis for engagement by complement factor H of C3b on a self surface.". Nat Struct Mol Biol18 (4): 463–70. doi:10.1038/nsmb.2018. PMID21317894.|displayauthors= suggested (help)
^Kajander, T.; Lehtinen, MJ.; Hyvärinen, S.; Bhattacharjee, A.; Leung, E.; Isenman, DE.; Meri, S.; Goldman, A. et al. (Feb 2011). "Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.". Proc Natl Acad Sci U S A108 (7): 2897–902. doi:10.1073/pnas.1017087108. PMID21285368.|displayauthors= suggested (help)
^ abAslam M, Perkins SJ. (June 2001). "Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling". J Mol Biol.309 (25): 1117–1138. doi:10.1006/jmbi.2001.4720. PMID11399083.
^Hughes, Anne E; Orr, Nick; Esfandiary, Hossein; Diaz-Torres, Martha; Goodship, Timothy; Chakravarthy, Usha (2006). "A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration". Nature Genetics38 (10): 1173–1177. doi:10.1038/ng1890. PMID16998489.
^Fritsche, L. G.; Lauer, N.; Hartmann, A.; Stippa, S.; Keilhauer, C. N.; Oppermann, M.; Pandey, M. K.; Kohl, J. et al. (2010). "An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD)". Human Molecular Genetics19 (23): 4694–4704. doi:10.1093/hmg/ddq399. PMID20843825.|displayauthors= suggested (help)
^Jokiranta, T S; Westin J, Nilsson U R, Nilsson B, Hellwage J, Löfås S, Gordon D L, Ekdahl K N, Meri S (Mar 2001). "Complement C3b interactions studied with surface plasmon resonance technique". Int. Immunopharmacol. (Netherlands) 1 (3): 495–506. doi:10.1016/S1567-5769(00)00042-4. ISSN1567-5769. PMID11367533.Cite uses deprecated parameters (help)
^Büttner-Mainik, A., J. Parsons, H. Jérome, A. Hartmann, S. Lamer, A. Schaaf, A. Schlosser, P.F. Zipfel, R. Reski, E.L. Decker (2011): Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnology Journal, doi:10.1111/j.1467-7652.2010.00552.x. 
^Schmidt, CQ.; Slingsby, FC.; Richards, A.; Barlow, PN. (Apr 2011). "Production of biologically active complement factor H in therapeutically useful quantities.". Protein Expr Purif76 (2): 254–63. doi:10.1016/j.pep.2010.12.002. PMID21146613.
Kardys, I. et al. (2006). "A common polymorphism in the complement factor h gene is associated with increased risk of myocardial infarction the rotterdam study". J. Am. Coll. Cardiol.47 (8): 1568–75. doi:10.1016/j.jacc.2005.11.076. PMID16630992.
Pío R, Elsasser TH, Martínez A, Cuttitta F (2002). "Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma". Microsc. Res. Tech.57 (1): 23–7. doi:10.1002/jemt.10047. PMID11921353.